Hazem Mslati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hazem Mslati has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Gentile
Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada
1 shared publication - Heikki Joensuu
Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki, Finland
1 shared publication - Humphrey Fonge
Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada
1 shared publication - Jeffrey Victor Leyton
School of Pharmaceutical Sciences, Faculty of Medicine University of Ottawa Ottawa Ontario Canada
1 shared publication - Jessica Pougoue Ketchemen
Faculté de Pharmacie, Université Laval, Ferdinand Vandry Pavillon, Québec, QC G1V 0A6, Canada; Axe Oncologie, Centre de Recherche du CHU (CRCHU) de Québec-Université Laval, Québec, QC G1J 5B3, Canada
1 shared publication - Léon Sanche
Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
1 shared publication
Latest Publications
- Open Access
- 22 April 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (5) , 606
Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering
Antibody-based agents have become a preferred treatment for various diseases, including cancer, due to significant advances in antibody engineering. The use of single-chain Fv-Fcs (scFv-Fcs) has been a promising engineering approach for therapeutic design. The concept is that the Fc provides increased stability and target binding and ultimately improves performance. However, the structural and dynamic relationship between the variable and Fc domains, which are fused in close proximity, and the impact on stability and target binding are not well understood. This study evaluated trastuzumab-derived scFv-Fc antibodies, focusing on the impact of their design on important biopharmaceutical parameters. Computational modelling and molecular dynamics, alongside experimental studies, were used to ascertain their dynamics, expression and purification, stabilities, and binding potencies. The results showed that the scFv subunits exhibited stochastic interplays that lead to diverse shapes and were associated with functional performance. This new understanding of scFv-Fc antibodies and their structural and functional nuances provides important details to further guide the design of more effective and less toxic therapeutics.
- 22 April 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (5) , 606
Open AccessIntegrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering
Antibody-based agents have become a preferred treatment for various diseases, including cancer, due to significant advances in antibody engineering. The use of single-chain Fv-Fcs (scFv-Fcs) has been a promising engineering approach for therapeutic design. The concept is that the Fc provides increased stability and target binding and ultimately improves performance. However, the structural and dynamic relationship between the variable and Fc domains, which are fused in close proximity, and the impact on stability and target binding are not well understood. This study evaluated trastuzumab-derived scFv-Fc antibodies, focusing on the impact of their design on important biopharmaceutical parameters. Computational modelling and molecular dynamics, alongside experimental studies, were used to ascertain their dynamics, expression and purification, stabilities, and binding potencies. The results showed that the scFv subunits exhibited stochastic interplays that lead to diverse shapes and were associated with functional performance. This new understanding of scFv-Fc antibodies and their structural and functional nuances provides important details to further guide the design of more effective and less toxic therapeutics.